Skip to main content
. Author manuscript; available in PMC: 2017 Oct 10.
Published in final edited form as: Cancer Res. 2016 Oct 7;76(23):6937–6949. doi: 10.1158/0008-5472.CAN-16-1899

Figure 6. Genetic interactions among E2A-PBX1 target genes reveal effective combination therapies.

Figure 6

(A) Upper panel, western blot shows the expression of indicated proteins. GAPDH was used as loading control. Lower panel, cell concentration of shRNA transduced cells relative to control transduced cells (shLuc) 5 days after sorting. Cell numbers were quantified by trypan blue exclusion assay. Data represent mean ± SEM (n=4 independent experiments). Statistical analysis by Student's t-test. (B) Dot plots show the proportion of GFP+ and mCherry+ cells at day 18 in flow cytometry from a representative experiment in which RCH-ACV cells were transduced with shRNA for luciferase (GFP) or ZAP70 (mCherry) and mixed 50/50 at day 0. Cells were cultured in the presence of vehicle or A770041 (500 nM) for 18 days. (C) Diagrams showing % of mCherry+ cells transduced from foregoing experiment and treated with the indicated compounds for 18 days: dasatinib (20 nM), R406 (500 nM) and A770041 (500 nM). Data represent mean ± SEM (n=3 independent experiments).